Integra LifeSciences Holdings Corporation is announcing its plans to restart the manufacture of PriMatrix® and SurgiMend at its new manufacturing facility in Braintree, Massachusetts. The Company expects to operationalize this new facility in the first half of 2026. Since receiving the third-party audit findings for its Boston, Massachusetts, manufacturing facility in March, the Company has been thoroughly reassessing its plans and timeline to resume the manufacture of PriMatrix and SurgiMend at this site.

In parallel, the Company has been furthering its plans to complete the construction and operationalization of its new tissue manufacturing facility in Braintree. Based on these assessments, the Company no longer plans to restart the manufacture of these products at its Boston facility and will, instead, restart manufacturing of these products at the Braintree site. Integra will temporarily utilize the Boston site and equipment to support product and process development activities to facilitate a smooth transition to the Braintree facility.

The company innovate treatment pathways to advance patient outcomes and set new standards of surgical, neurologic, and regenerative care. The company offer a comprehensive portfolio of high quality, leadership medical technology brands.